Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1986 Jun;21(6):627–632. doi: 10.1111/j.1365-2125.1986.tb05226.x

Plasma catecholamines following exercise in hypertensives treated with pindolol: comparison with placebo and metoprolol.

R Vandongen, B Margetts, N Deklerk, L J Beilin, P Rogers
PMCID: PMC1400981  PMID: 3741714

Abstract

This study re-examines the proposal that beta-adrenoceptor blockers with intrinsic sympathomimetic activity decrease plasma noradrenaline levels. Thirteen patients (aged 29-65 years) with uncomplicated essential hypertension were randomly allocated to a three period, double-blind cross-over trial. The treatment periods, each of 3 weeks duration, were composed of placebo, pindolol (5 mg twice daily) and metoprolol (100 mg twice daily), dispensed in identical capsules. At the end of each treatment period, patients were exercised on a bicycle ergometer to a predetermined workload. Blood pressure and heart rate were measured before, immediately on completion of exercise and after 10 min post-exercise rest. Blood samples for plasma noradrenaline and adrenaline determination were also collected at these times. Blood pressures were similar during treatment with pindolol and metoprolol. As expected, heart rate was consistently lower during metoprolol treatment. Basal, pre-exercise plasma noradrenaline and adrenaline were similar at the end of each treatment period. However, the increase following exercise was significantly greater during metoprolol treatment. The post-exercise increase during pindolol treatment was indistinguishable from that in the placebo period. These findings, in a randomised placebo-controlled study, therefore demonstrate that pindolol does not influence basal or exercise-stimulated plasma noradrenaline and adrenaline concentrations. This is best explained by a lack of effect of pindolol on the plasma clearance of catecholamines, which is impaired by beta-adrenoceptor blockers devoid of intrinsic sympathomimetic activity.

Full text

PDF
627

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Best J. D., Halter J. B. Blood pressure and norepinephrine spillover during propranolol infusion in humans. Am J Physiol. 1985 Apr;248(4 Pt 2):R400–R406. doi: 10.1152/ajpregu.1985.248.4.R400. [DOI] [PubMed] [Google Scholar]
  2. Davidson L., Vandongen R., Beilin L. J., Arkwright P. D. Free and sulfate-conjugated catecholamines during exercise in man. J Clin Endocrinol Metab. 1984 Mar;58(3):415–418. doi: 10.1210/jcem-58-3-415. [DOI] [PubMed] [Google Scholar]
  3. Esler M., Jackman G., Leonard P., Skews H., Bobik A., Jennings G. Effect of propranolol on noradrenaline kinetics in patients with essential hypertension. Br J Clin Pharmacol. 1981 Sep;12(3):375–380. doi: 10.1111/j.1365-2125.1981.tb01229.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Franz I. W., Lohmann F. W., Koch G. Differential effects of long-term cardioselective and nonselective beta-receptor blockade on plasma catecholamines during and after physical exercise in hypertensive patients. J Cardiovasc Pharmacol. 1980 Jan-Feb;2(1):35–44. doi: 10.1097/00005344-198001000-00005. [DOI] [PubMed] [Google Scholar]
  5. Frishman W. H. Drug therapy. Pindolol: a new beta-adrenoceptor antagonist with partial agonist activity. N Engl J Med. 1983 Apr 21;308(16):940–944. doi: 10.1056/NEJM198304213081606. [DOI] [PubMed] [Google Scholar]
  6. Kirsten R., Heintz B., Böhmer D., Nelson K., Roth S., Welzel D. Relationship of plasma catecholamines to blood pressure in hypertensive patients during beta-adrenoceptor blockade with and without intrinsic sympathomimetic activity. Br J Clin Pharmacol. 1982;13(Suppl 2):397S–406S. doi: 10.1111/j.1365-2125.1982.tb01947.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Macdonald I. A., Bennett T., Brown A. M., Wilcox R. G., Skene A. M. The effects of acute or chronic ingestion of propranolol or metoprolol on the metabolic and hormonal responses to prolonged, submaximal exercise in hypertensive men. Br J Clin Pharmacol. 1984 Mar;17(3):283–293. doi: 10.1111/j.1365-2125.1984.tb02343.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Man in 't Veld A. J., Schalekamp M. A. How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism. Br J Clin Pharmacol. 1982;13(Suppl 2):245S–257S. doi: 10.1111/j.1365-2125.1982.tb01922.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. McGrath B. P., Beilin L. J., Schofield T., Benedict C. R., Barker N. P., Cooper R. Home blood pressure monitoring and changes in plasma catecholamines during once or twice daily treatment with atenolol in patients with mild hypertension. Aust N Z J Med. 1979 Aug;9(4):374–381. doi: 10.1111/j.1445-5994.1979.tb04162.x. [DOI] [PubMed] [Google Scholar]
  10. Myers M. G., de Champlain J. Effects of atenolol and hydrochlorothiazide on blood pressure and plasma catecholamines in essential hypertension. Hypertension. 1983 Jul-Aug;5(4):591–596. doi: 10.1161/01.hyp.5.4.591. [DOI] [PubMed] [Google Scholar]
  11. Peuler J. D., Johnson G. A. Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. Life Sci. 1977 Sep 1;21(5):625–636. doi: 10.1016/0024-3205(77)90070-4. [DOI] [PubMed] [Google Scholar]
  12. Plotnick G. D., Fisher M. L., Wohl B., Hamilton J. H., Hamilton B. P. Improvement in depressed cardiac function in hypertensive patients during pindolol treatment. Am J Med. 1984 Jan;76(1):25–30. doi: 10.1016/0002-9343(84)90740-x. [DOI] [PubMed] [Google Scholar]
  13. Rahn K. H., Gierlichs H. W., Planz G., Planz R., Schols M., Stephany W. Studies on the effects of propanolol on plasma catecholamine levels in patients with essential hypertension. Eur J Clin Invest. 1978 Jun;8(3):143–148. doi: 10.1111/j.1365-2362.1978.tb00827.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES